Showing results (271-280 of 287) with videos related to

Sort By:
Pageof 29
Journal of Internal Medicine|July 7, 2017
Impact of immunosuppressive therapy on therapy-neutralizing antibodies in transplanted patients with Fabry diseaseM Lenders, D Oder, A Nowak, et al.
Acta Neurologica Scandinavica|July 1, 1997
Linkage analysis between idiopathic generalized epilepsies and the GABA(A) receptor alpha5, beta3 and gamma3 subunit gene cluster on chromosome 15T Sander, R Kretz, M P Williamson, et al.
Epilepsy Research|April 1, 1996
Exclusion of linkage between idiopathic generalized epilepsies and the GABAA receptor alpha 1 and gamma 2 subunit gene cluster on chromosome 5T Sander, T Hildmann, D Janz, et al.
Oncotarget|May 8, 2018
Non-invasive tumor genotyping using radiogenomic biomarkers, a systematic review and oncology-wide pathway analysisRobin W Jansen, Paul van Amstel, Roland M Martens, et al.
British Journal of Cancer|July 2, 2014
Epidermal growth factor receptor (EGFR) and prostaglandin-endoperoxide synthase 2 (PTGS2) are prognostic biomarkers for patients with resected colorectal cancer liver metastasesJ A C M Goos, A C Hiemstra, V M H Coupé, et al.
Neurology|August 26, 2011
Factors influencing in-hospital mortality and morbidity in patients treated on a stroke unitHans-Christian Koennecke, W Belz, D Berfelde, et al.
Breast (Edinburgh, Scotland)|December 14, 2025
Trends in local, regional and contralateral breast tumor recurrence within five years after diagnosis in the Netherlands: a population-based study including 121347 patientsJ Meijer, H J G D van den Bongard, L B Koppert, et al.
The American Journal of Surgical Pathology|July 9, 2019
Decalcification of Breast Cancer Bone Metastases With EDTA Does Not Affect ER, PR, and HER2 ResultsSuzanne C van Es, Bert van der Vegt, Frederike Bensch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 25, 2015
Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trialG Gebhart, L E Lamberts, Z Wimana, et al.
Urologic Oncology|October 20, 2022
Biology of BCG response in non-muscle invasive bladder cancer - 2021 IBCN Updates Part IIIM J Reike, M A Ingersoll, D C Müller, et al.
Pageof 29